NCT06376669Not yet recruiting

Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Name: Clinical Trial NCT06376669
Creator: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Keywords: Renal Cell Carcinoma, Proton Stereotactic Body Radiation therapy (SBRT), Phase 2, radiation, clinical trial

Prospective Phase II Study of Stereotactic Body Proton Therapy for Treatment of PrimAry Renal Cell Carcinoma (SPARE)

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2ClinicalTrials.govradiation

Verified

Study focus

Disease/Condition: Renal Cell Carcinoma
Drug/Device/Intervention: Proton Stereotactic Body Radiation therapy (SBRT)
Study type: Interventional
Intervention type: radiation

Sponsor & location

Primary sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Timeline & enrollment

Phase: Phase 2
Start date: Jun 01, 2024
End date: Aug 01, 2030
Enrollment: 20 participants

Primary outcome

Change in kidney function after PROTON-BASED SBRT treatment as assessed by serum creatine levels,Change in kidney function after PROTON-BASED SBRT treatment as assessed by estimated glomerular rate (eGFR) values

Summary

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

ICD-10 classifications

Malignant neoplasm of kidney, except renal pelvisMalignant neoplasm of renal pelvisSecondary malignant neoplasm of kidney and renal pelvisBenign neoplasm: KidneyBenign neoplasm: Renal pelvis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06376669
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06376669 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and is currently Not yet recruiting. The study focuses on Renal Cell Carcinoma. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.